This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes assessed were: ventilation-perfusion results in patients with and without adequate cardiorespiratory reserve, Doppler ultrasound with B mode sensitivity for deep vein thrombosis (DVT) in patients with PE, and the additional detection rate with serial testing if the initial ultrasound was negative.
Study designs and other criteria for inclusion in the review
The study designs were not specifically reported.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Four primary studies were included in the review. This number excluded the authors' prior decision analysis.
Methods of combining primary studies
The primary studies were combined in a narrative.
Investigation of differences between primary studies
Results of the review
Of the 662 patients, 56% had adequate cardiorespiratory reserve. In this sub-set of 370 patients, ventilation-perfusion scans were near-normal in 72, nondiagnostic in 255, and of high probability in 43.
In patients with inadequate cardiorespiratory reserve (n=292), ventilation-perfusion scans were near-normal in 33, nondiagnostic in 213, and of high probability in 46.
A single Doppler would detect DVT in 50% of patients with PE.
In 3% of patients with adequate cardiorespiratory reserve and negative initial ultrasound, serial ultrasound would detect DVT.
In all strategies, 105 patients had near normal results in the lung scan (treatment subsequently withheld) and 89 of them had high probability scans (and were assumed to be treated).
Measure of benefits used in the economic analysis
Two criteria of effectiveness were used. These were the correct identification of venous thromboembolism; and the correct identification of the number of patients in whom treatment was correctly withheld.
Direct costs
The quantity/cost boundary adopted was that of a third-party payer (health service perspective). The costs included were those for each diagnostic strategy (including physician or specialist charges for interpretation) plus the costs of treating patients who had positive results. The treatment costs included anticoagulant therapy (drugs, laboratory tests, physician fees), hospital "hotel" costs, and the costs of anticoagulant therapy for side effects. Side effects of pulmonary angiography were excluded as they were considered to be non significant. The initial clinical examination was also excluded because it was common to all strategies. The quantities were partly derived from data and partly using modelling. Although some long-term cost components were included in the study (e.g. long-term warfarin treatment of PE), the authors did not report whether discounting was carried out. The quantities and the costs were analysed and reported separately. More detailed cost information can be obtained from the authors if required. The quantities were derived from trials published in 1990 and 1992. The costs came from an urban teaching hospital in western Canada and the price year was 1999 (inflation-adjusted from original data from 1992).
Statistical analysis of costs
The costs were treated deterministically and no statistical analysis was carried out.
Indirect Costs
The indirect costs were not included.
Currency
Canadian dollars (Can$).
Sensitivity analysis
Multiple sensitivity analyses were carried out to evaluate variations in the costs of a hospital bed, treatment and diagnostic tests, and the impact of false-positive tests on noninvasive testing. Variations in PE prevalence in symptomatic patients were also analysed to evaluate generalisability. The ranges used were based on authors' assumptions. The costs of secondary investigation with electrocardiography, chest X-ray, and so on (which common to all strategies) were also evaluated in a sensitivity analysis.
Estimated benefits used in the economic analysis
In strategy 1, all patients with nondiagnostic results (468) Thus, the total number of patients suspected of requiring treatment was 194 with strategy 1, 195 with strategy 2 and 169 with strategy 3.
